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Abstract: Mitochondrial DNA mutations play an important role in causing sensorineural 
hearing loss. The purpose of this study was to determine the association of the mitochondrial 
genes RNR1, MT-TL1, and ND1 as well as the nuclear genes GJB2 and GJB6 with audiological 
examinations in nonfamilial Iranians with cochlear implants, using polymerase chain reaction, 
DNA sequencing, and RNA secondary structure analysis. We found that there were no novel 
mutations in the mitochondrial gene 12S rRNA (MT-RNR1) in patients with and without GJB2 
mutation (GJB2+ and GJB2-, respectively), but a total of six polymorphisms were found. 
No mutations were observed in tRNALeu(UUR) (MT-TL1). Furthermore, eight polymorphisms were 
found in the mitochondrial ND1 gene. Additionally, no mutations were observed in the nuclear 
GJB6 gene in patients in the GJB2- and GJB2+ groups. The speech intelligibility rating and 
category of auditory perception tests were statistically assessed in patients in the GJB2- and 
GJB2+ groups. The results indicated that there was a significant difference (P,0.05) between 
the categories of auditory perception score in the GJB2- group compared to that in the GJB2+ 
group. Successful cochlear implantation was observed among individuals with GJB2 mutations 
(GJB2+) and mitochondrial polymorphisms compared to those without GJB2 mutations (GJB2-). 
In conclusion, the outcome of this study suggests that variation in the mitochondrial and nuclear 
genes may influence the penetrance of deafness. Therefore, further genetic and functional studies 
are required to help patients in making the best choice for cochlear implants.
Keywords: mitochondrial 12S rRNA (MT-RNR1) gene, mitochondrial tRNALeu(UUR) (MT-TL1) 
gene, MT-ND1, nuclear GJB2 and GJB6 genes, cochlear implant, sensorineural hearing loss
Introduction
Hearing loss (HL) is one of the most common sensory disorders in humans affecting 
one to three of every 1,000 newborns.1 The onset of HL usually occurs in childhood, is 
predominantly postlingual, and may be accompanied by vertigo2 and tinnitus.3,4 There 
is a high variability in severity, ranging from normal hearing to profound deafness.5,6 
This may be due to the fact that the phenotypic effects are a result of several factors 
and can develop gradually.7 HL occurs in both syndromic and nonsyndromic deaf-
ness caused by mitochondrial DNA (mtDNA) mutations,8 where both environmental 
and genetic factors are also involved, such as noise pollution, use of aminoglycoside 
drugs, and genomic diversity.9 mtDNA mutations are responsible for both mater-
nally inherited syndromic and nonsyndromic HL and play a role in predisposition to 
aminoglycoside-induced ototoxicity.10 In Italy, at least 5% of cases of postlingual, non-
syndromic hearing impairment may be attributed to mtDNA mutations.1 Furthermore, 
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it has been estimated that in up to 67% of patients with and 
without GJB2 mutations (GJB2+ and GJB2-, respectively), 
mtDNA disorders also manifest as sensorineural hearing 
loss (SNHL).11 SNHL associated with mtDNA mutations is 
generally progressive with high frequency.12–15 This may be 
explained by the high oxidative phosphorylation demands in 
cochlear cells, as conveyed by mtDNA mutations.1
Human mtDNA is a 16,569-bp, circular, double-stranded 
molecule that encodes 37 genes, including 13 subunits of the 
respiratory chain complexes, two ribosomal RNAs, and 22 
transfer RNAs. Each nucleated human cell contains a few 
thousand copies of mtDNA. The somatic mutation rate of 
mtDNA is presumed to be 10–20 times higher than that of 
nuclear DNA (nDNA).16 Mitochondria are essentially double-
membraned subcellular organelles present in all nucleated 
mammalian cells. Their primary function is to support aerobic 
respiration, that is, the production of adenosine triphosphate 
through oxidative phosphorylation.17 In addition, mutations 
and/or polymorphism variance in mitochondrial genes play 
important roles and are related to many diseases, such as 
Leber’s hereditary optic neuropathy,18 Friedreich’s ataxia,19 
autism,20 Alzheimer’s disease,21 oculocutaneous albinism 
type 1,22 recurrent pregnancy loss,23 and different cancers, 
such as gastric,24,25 bladder,26 colorectal,27 and breast.24
HL is caused by genetic or nongenetic factors. The 
nongenetic risk factors for HL during the neonatal period 
include treatment in a neonatal intensive care unit, cran-
iofacial anomalies, meningitis,28,29 and cytomegalovirus 
infections.30 mtDNA variants, including mutations, deletions, 
and insertions, particularly in the MT-RNR1 gene, have been 
identified to play an important role in patients with SNHL 
associated with or without a history of aminoglycoside 
therapy, suggesting that this locus in particular is a hotspot 
for deafness-associated mutations.31,32 The MT-TL1 gene 
encoding mitochondrial tRNALeu(UUR) is a hotspot for patho-
genic mtDNA mutations,33 and a previous study reported the 
possible role of MT-TL1 in nonsyndromic disease.9 Muta-
tions in this region cause severe myopathy with respiratory 
insufficiency,33,34 as this region is highly conserved among 
mammals.35 mtDNA mutations, in particular T3308C, have 
been identified to induce a significant decrease in the levels 
of the MT-ND1 gene, suggesting that mutations in this region 
can increase the penetrance of deafness in patients with 
HL.1,36 Mutations in the nuclear GJB2 and GJB6 genes on 
the DFNB1 locus at chromosome 13q11-q12 are responsible 
for up to 50% of the most common causes of prelingual 
onset, recessively inherited nonsyndromic SNHL in humans, 
encoding the gap junction proteins connexin 26 (Cx26) and 
connexin 30, respectively,37,38 and play a role in cochlear 
homeostasis.39 Recessive mutations in the GJB2 gene are the 
most common cause of hearing impairment40 affecting both 
paternal and maternal alleles.40,41 Thus, in order to estimate 
the incidence ratio of mutation in the next generation, the 
frequency of the mutation is to be ascertained.41,42 The GJB2 
gene is the most common cause of the congenital HL,43 and 
the mutation spectra are different among different ethnic 
groups.42 It is essential to investigate the carrier frequency 
and mutation spectrum of each genetic background in order 
to provide more precise genetic counseling. The GJB2 gene 
encodes Cx26, a member of the connexin family of proteins 
that are constituents of the intercellular gap junction.44 The 
first GJB2 mutation was reported by Kelsell et al,45 in which 
c.35delG is the most common mutation in the Caucasian 
population while c.235delC and p.Val37Ile are the most 
common mutations in the Asian population.42,46 In this study, 
we aimed to compare the impact of mutations in the mito-
chondrial 12S rRNA (MT-RNR1), tRNALeu(UUR) (MT-TL1), 
and ND1 on Iranian patients with nuclear GJB2 mutation 
(GJB2+) and without GJB2 mutation (GJB2-) undergoing 
cochlear implants.
Materials and methods
specimen collection and ethical statement
In this study, blood samples from 84 patients who had prelin-
gual deafness with normal cochlear structures were obtained 
from the Rasoul Akram Hospital, Tehran, Iran. The patients 
did not show any syndromic symptoms or other clinical 
abnormalities, including muscular diseases, diabetes, visual 
dysfunction, or neurological disorders. Eighty-four patients 
with cochlear implant were categorized into two groups 
including 24 patients without GJB2 (GJB2-) mutations and 
60 patients with GJB2 (GJB2+) mutations. Written informed 
consent, including consent to participate in this study and 
consent to submission and publish, was obtained from the 
parents on behalf of their children in accordance with the 
Medical Ethics Committee of Rasoul Akram Hospital, 
Tehran, Iran (Approval No 375/105/D/93).
audiological examinations
Categories of auditory performance (CAP)47 and speech intel-
ligibility rating (SIR)48 were used to assess hearing ability and 
speech intelligibility, respectively. The infants were screened 
at 2 months of age and were then referred to an audiologist 
after 2 years of age for audiometric tests, including CAP and 
SIR tests, where profound HLs (.90 dB) were identified in 
the patients. In the CAP test, the rating of auditory ability 
consists of the following eight categories:47 Score 0 – no 
awareness of environmental sounds; Score 1 – awareness 
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of environmental sounds; Score 2 – response to speech 
sounds; Score 3 – recognition of environmental sounds; 
Score 4 – discrimination of at least two speech sounds; Score 
5 – understanding of common phrases without lip reading; 
Score 6 – understanding of conversation without lip reading 
with a familiar talker; and Score 7 – use of a telephone with 
a familiar talker. The SIR test consists of five categories.48 
Scores 1–5 depend on the spoken ability rating scale criteria, 
which are as follows: 5 – connected speech is intelligible to 
all listeners and the child is understood easily in everyday 
contexts; 4 – connected speech is intelligible to a listener 
who has a little experience of a deaf person’s speech; 3 – 
connected speech is intelligible to a listener who concentrates 
and lip-reads; 2 – connected speech is unintelligible, where 
intelligible speech is developing single words when context 
and lip-reading cues are available; and 1 – connected speech 
is unintelligible, where prerecognizable words in spoken 
language, the primary mode of communication, may be 
manual. All children received early intervention services 
within an average of 2 months after identification. This 
study was conducted in the Cochlear Implant Centre of the 
Hazrat Rasoul Akram Medical Complex, Tehran, Iran. The 
CAP and SIR assessments were conducted by two speech 
therapists during the follow-up period before implantation 
and at 6 months, 1 year, and 2 years after implantation. All 
84 subjects had scores for both CAP and SIR before and after 
implantation. The children had to orally repeat the words/
sentences they heard from the test conductor who produced 
the stimuli with his/her mouth covered (all the subjects were 
tested by the same conductor) and were scored based on the 
number of (key)words they correctly repeated. The answers 
were then recorded.
Dna extraction and polymerase chain 
reaction
Total DNA was extracted from the peripheral blood sample of 
each individual using a QIAmap DNA Micro Kit (QIAGEN 
no 56304). The DNA was amplified for the mitochondrial 12S 
rRNA, tRNALeu(UUR), and ND1 genes (located near the MT-TL1 
gene) and also for the nuclear GJB2 and GJB6 genes, using 
specific primers (Table 1).
Briefly, polymerase chain reaction (PCR) was performed 
in 25 μL of reaction volumes containing 50–100 ng of 
genomic DNA, 2.5 μL of 10× PCR buffer, 10 mM of each 
dNTP, 1 mM of MgCl
2
, 10 pmol of each primer, and 5 U of 
Taq polymerase (CinnaGen, Tehran, Iran) to a final volume 
of 25 μL, topped up using distilled water. The reactions 
were performed in a thermal cycler (Eppendorf, Humburg, 
Germany), and the PCR products were examined on 1.5% 
agarose gel electrophoresis. The PCR conditions for amplifi-
cation of the mitochondrial 12S rRNA were as follows: initial 
DNA denaturation at 95°C for 5 minutes, then 35 cycles of 
denaturation at 95°C for 1 minute, annealing at 50°C for 
1 minute, and extension at 72°C for 1 minute, followed by 
final extension at 72°C for 10 minutes. The PCR conditions 
for amplification of the mitochondrial tRNALeu(UUR) were as 
follows: initial DNA denaturation at 94°C for 5 minutes, then 
35 cycles of denaturation at 94°C for 50 seconds, annealing at 
55°C for 50 seconds, and extension at 72°C for 45 seconds, 
followed by final extension at 72°C for 10 minutes.
The primer sequences for the GJB6 gene used in this 
study were in accordance with previous studies.49–51 How-
ever, neither mutations nor deletions have been identified 
in the GJB6 gene in our patients. The PCR conditions for 
amplification of the nuclear GJB6 gene were as follows: 
initial DNA denaturation at 95°C for 5 minutes, then 35 
cycles of denaturation at 95°C for 1 minute, annealing at 
58.5°C for 1 minute, and extension at 72°C for 1 minute, 
followed by final extension at 72°C for 10 minutes. The PCR 
conditions for amplification of the nuclear GJB2 gene were 
performed in two steps, after initial DNA denaturation at 
93°C for 3 minutes. The first step was done with five cycles 
of denaturation at 95°C for 1 minute, annealing at 59°C for 
1 minute, and then final extension at 72°C for 1 minute. 
Table 1 PCR primers of selected nuclear and mitochondrial genes
Name Gene Primer name Primer sequences TM (°C) Amplicon size (bp)
12S rRNA MT-RNR1 ng 78-F F: 5′-CagCaCaCaCaCaCCgCTgC-3′ 57.2 950
ng 81-R R: 5′-gCTaaggTTgTCTggTagTa-3′
tRNALeu(UUR) MT-TL1a OnP 82-F F: 5′-CTCaaCTTagTaTTaTaCCC-3′ 57.2 300
OnP 164-R R: 5′-gaTggTgagagCTaaggTCg-3′
Connexin 26 GJB2 Cxn 26-F F: 5′-CTCCCTgTTCTgTCCTagCT-3′ 59 800
Cxn 26-R R: 5′-CTCaTCCCTCTCaTgCTgTC-3′
Connexin 30 GJB6 Cxn 30-F F: 5′-CaCTTTCCCaaggCCTCTTC-3′ 58.5 850
Cxn 30-R R: 5′-ggTTggTaTTgCCTTCTgga-3′
Note: aND1 gene is covered by MT-Tl1 primers.
Abbreviations: PCR, polymerase chain reaction; F, forward; R, reverse; TM, temperature.
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The second step was carried out with 26 cycles of denatur-
ation at 94°C for 45 seconds, annealing at 59°C for 45 sec-
onds, and extension at 72°C for 45 seconds, followed by final 
extension at 72°C for 8 minutes.
Dna sequencing and analysis of variants
The PCR products were sequenced with the respective for-
ward or reversed primers on an ABI 3700 sequencer (Takapo 
Zist Company, Tehran, Iran) and compared with the revised 
Cambridge Reference Sequence and the NCBI Reference 
Sequence Database (http://www.ncbi.nlm.nih.gov/refseq/) 
using the FinchTV program version 1.4.0. Identification of 
the nucleotide changes was verified through MITOMAP 
(http://mitomap.org/MITOMAP) and the Human Gene Muta-
tion Database, 2007.
Rna secondary structure analysis
The RNA fold software from the Institute for Theoretical 
Chemistry, University of Vienna (rna@tbi.univie.ac.at; 
http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi), was used 
to predict the RNA secondary structure based on minimum 
energy requirements and base pairing (Figures 1 and 2).
statistical analysis
The independent t-test using Statistical Package for the Social 
Sciences, version 13, was used to analyze the relationship 
between CAP and SIR with cochlear implantation in the 
GJB2- and GJB2+ groups; P-values ,0.05 were regarded 
as statistically significant (Table 2).
Results
In this study, the MT-RNR1 (12sRNA) and MT-TL1 
(tRNALeu(UUR)) genes were analyzed. Polymorphisms that 
were detected in MT-RNR1 included G709A in eight patients 
(9.6%), T1243C in two patients (2.4%), T980C in three 
patients (3.6%), T1406C in one patient (1.2%), G930A in 
one patient (1.2%), and T1189C in three patients (3.6%). 
No mutation was found in the MT-TL1 (tRNALeu(UUR)) gene. 
Figure 1 (Continued)
Polymorphism (B)Wild type (A)GeneGroup
GJB2– patient   T980C (MT-RNR1) 
T T TC C C C CA G
700
T T TC C C C CCA AG
690
C C C C C CT T TA G
150 150
T T T TC C C C C CT T A AG
650
T T T TC C C C CCA A
640
T T TC C C C C C CA A AG
170
C C C C C CT T G
430
A A A A AC T A
430
A A A T TC C C CA
GJB2– patient/
GJB2+ patient  
G709A
(MT-RNR1)
GJB2+ patient T1189C(MT-RNR1)
GJB2– patient   T1243C(MT-RNR1)
Therapeutics and Clinical Risk Management 2016:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
audiological examinations in iranian patients with hl
Polymorphism (B)Wild type (A)GeneGroup
GJB2– patient
GJB2– patient
GJB2– patient
T1406C
(MT-RNR1)
AC A AC C C CT T
290
A AC C C C C CC T T
290
G G
C C C A AT T T TG
120
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–
A3505G
(MT-ND1)
G3337A
(MT-ND1)
GJB2+ patient
C C CA A A A G A G
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C C C C CA A T TG G
210
C C C CA A A T T
210
C C CT A A A AG G
270
A3480G
(MT-ND1)
GJB2+ patient
G3421A
(MT-ND1)
GJB2– patient A3360G
(MT-ND1)
C CA AA T T TG G
150
C C CA A T T TG G GG
150
CC
Figure 1 (Continued)
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Figure 1 Comparison of sequence analysis of the polymorphism in MT-RNR1 and MT-ND1 and heterozygous GJB2 genes among patients with gJB2 mutation (gJB2+) and 
without gJB2 mutation (gJB2-).
Note: The arrows indicate the location of the nucleotide changes in wild type vs polymorphism.
GJB2
hetrozygote 
in GJB2+ patient
35delG
heterozygote
C C T T TG G G G G G G
9080
C T G G G G G G G
90
G G
Wild type (A)GeneGroup Polymorphism (B)
Figure 2 (Continued)
Group Gene Wild type (A) Polymorphism (B)
GJB2– patient T980C
(MT-RNR1)
GJB2–
patient/GJB2+ 
patient
A709G
(MT-RNR1)
GJB2+ patient 
GJB2– patient T1406C
(MT-RNR1)
G930A
(MT-RNR1)
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Table 2 statistical analysis of siR and CaP in the gJB2- and gJB2+ patients using independent t-test
Audiological 
examinations
Before cochlear implantation (mean ± SD) After cochlear implantation (mean ± SD) P-value
GJB2+ patient (N=60) GJB2- patient (N=24) GJB2+ patient (N=60) GJB2- patient (N=24)
siR 1±0 1±0 2.93±0.54 2.92±0.88 0.663
CaP 1±0 1±0 6.75±1.36 5.58±0.79 0.002*
Notes: There is a significant difference (P,0.05) between the CaP score of gJB2- patients compared to gJB2+ patients, while there is no significant difference in the SIR 
score between gJB2- and gJB2+ patients. The score of CaP in gJB2+ patients is higher than that of gJB2- patients, which shows that this group comprises better candidates 
for cochlear implant than the other group. CAP and SIR assessments were done 2 years after cochlear implant. *Statistically significant (P,0.05).
Abbreviations: siR, speech intelligibility rating; CaP, category of auditory performance; sD, standard deviation.
GJB2+ patient T1189C
(MT-RNR1)
GJB2+ patient A3480G
(MT-ND1)
GJB2– patient G3337A
(MT-ND1)
Group Gene Wild type (A) Polymorphism  (B)
Figure 2 Comparison of Rna secondary structure analysis of wild type and polymorphic predicted in MT-RNR1 and MT-ND1 genes among patients with gJB2 mutation 
(gJB2+) and without gJB2 mutation (gJB2-).
Note: The arrows indicate the location of the nucleotide changes based on Rna secondary structure analysis in wild type vs polymorphism.
Additionally, eight polymorphisms in the MT-ND1 (NADH 
dehydrogenase I) gene were found, including A3360G (1.2%), 
A3505G (2.4%), A3339G (1.2%), G3337A (2.4%), G3392C 
(1.2%), G3483A (1.2%), A3480G (3.6%), and G3421A 
(2.4%). Here, all mtDNA mutations were homoplasmic, while 
only one – A3339G (1.2%) – was heteroplasmic mtDNA 
ND1 polymorphism. Two GJB2+ patients with V153I and 
R184P did not show any mitochondrial RNR1 and ND1 muta-
tions. In addition, all GJB2- and GJB2+ patients revealed the 
presence of the A750G and A1438G polymorphisms in the 
MT-RNR1 gene. Sequence analysis in the nuclear GJB2 and 
GJB6 genes demonstrated that no mutation in nuclear GJB6 
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Figure 3 Frequency of polymorphism MT-RNR1 and MT-ND1 genes in patients without gJB2 mutation (gJB2-) and patients with gJB2 mutation (gJB2+).
Notes: (A) MT-ND1 gene and (B) MT-RNR1 gene.
gene was detected in all GJB2- and GJB2+ groups. Of the 84 
individuals, no GJB2 mutation was observed in 24 patients 
(GJB2-), but different types of GJB2 mutations were observed 
among the 60 GJB2+ patients (Table 3; Figure 3).
Discussion
In this study, the impact of the mitochondrial 12S rRNA (MT-
RNR1), tRNALeu(UUR) (MT-TL1), and ND1 variations among 
84 random Iranian patients were compared between patients 
with GJB2 mutation (GJB2+) and without GJB2 mutation 
(GJB2-) undergoing cochlear implants, which had not been 
examined by earlier Iranian researchers. These hotspots are 
recognized to be among the most frequent causes of hearing 
impairment.52 Mitochondria play an important function in 
metabolism, thus mutations in mitochondrial genes result in 
many metabolic diseases.53 In the present study, we analyzed 
three fragments of mtDNA, namely 12S rRNA (MT-RNR1), 
tRNALeu(UUR) (MT-TL1), and ND1, and two fragments of 
nDNA, namely GJB2 (Cx26) and GJB6, in 84 subjects with 
nonsyndromic HL. All patients (GJB2– and GJB2+) were 
found to have the A750G and A1438G polymorphisms in the 
MT-RNR1 gene, which is in agreement with previous studies 
that reported that the A750G, A1438G, A4769G, A8860G, 
and A15326G polymorphisms are common to mtDNA 
sequences from Africans, Asians, and Europeans.54 There-
fore, the polymorphisms in the MT-RNR1 gene are not the 
cause of deafness and hearing impairment in Iranian patients. 
However, among the eight polymorphisms in the MT-ND1 
(NADH dehydrogenase I) gene, A3505G and A3480G are 
associated with prostate cancer, while G3337A and G3421A 
are associated with cardiomyopathy55 and pancreatic cancer,56 
respectively.
It should be noted that late-onset and gradual worsen-
ing of hearing impairment may reflect the tendency of the 
mitochondrion to accumulate mutations with aging, due to its 
genomic instability. As previously reported,57 mitochondrial 
mutation plays an important role in cochlear implantation, 
whereas in our study, mitochondrial polymorphisms also 
indicate candidacy for cochlear implantation. Additionally, 
RNA secondary structure analysis demonstrated that the 
RNA at G930A, T1189C, and A3480G had different struc-
tures to compare the wild type, where it is possible that these 
polymorphisms and their correlation with the GJB2 mutation 
have more effect on deafness.
The association between mitochondrial and nuclear muta-
tions with aminoglycoside exposure is quite variable, where 
aminoglycosides are probably only one of the factors interact-
ing with the mutation in determining the deafness phenotype 
and play a role only in ~20% of patients.1,58–61 Several studies 
have reported that patients carrying the A1555G mutation 
exposed to aminoglycosides develop more severe deafness 
with an earlier onset.31,59,60,62–64 However, consistent with the 
other studies,58–61,65,66 our study showed that even in the absence 
of aminoglycoside exposure, mitochondrial polymorphisms 
could be responsible for hearing impairment. Previous studies 
revealed the mitochondrial m1555A.G,67 m.1005T.C,68 and 
m.921T.C68 mutations among Iranian patients, while these 
mentioned mutations were not detected in our patients with HL. 
Additionally, a study indicated the high carrier frequency of the 
nuclear GJB2 mutation (35delG) in the north of Iran.69
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Conclusion
In conclusion, our finding indicates that a combination of 
polymorphisms in mitochondrial and nuclear genes may 
increase the penetrance of deafness and that there may be 
an association between nuclear gene variation and mito-
chondrial deafness with cochlear implant in Iranian patients. 
Therefore, the pathogenicity impact of mtDNA and nDNA 
variants and their correlation with other conditions should be 
established. Therefore, further genetic and functional studies 
are required in order to help individuals decide whether to 
undergo cochlear implantation.
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